References
- Statistics about diabetes: overall numbers, diabetes, and prediabetes. Alexandria (VA): American Diabetes Association, 2016. Available at: http://www.diabetes.org/diabetes-basics/statistics/ [Last accessed 5 October 2016]
- Facts about type 2. Alexandria (VA): American Diabetes Association, 2015. Available at: http://www.diabetes.org/diabetes-basics/type-2/facts-about-type-2.html [Last accessed 5 October 2016]
- American Diabetes Association. Approaches to glycemic control: standards of medical care in diabetes – 2016. Diabetes Care 2016;39(Suppl1):S52-S9
- American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033-46
- Kaltenboeck A, Ivanova J, Binbaum H, et al. Costs after initiating saxagliptin, sulfonylurea or sitagliptin in patients with T2DM. Am J Pharm Benefits 2014;6:e60-9
- Vaidya V, Adhikari K, Sheehan J, et al. Comparison of charges and resource use associated with saxagliptin and sitgaliptin. Health Econ Rev 2016;6:26
- Farr AM, Sheehan JJ, Brouillette M, et al. Healthcare costs among adults with type 2 diabetes initiating DPP-4 inhibitors. Adv Ther 2016;33:68-81
- Consumer Price Index Detailed Report Tables. 2016. Available at: http://www.bls.gov/cpi/tables.htm [Last accessed 3 November 2016]
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
- Fowler R, Johnston SS. Comparative performance of risk adjustment measures in a sample of commercially-insured patients under age 65 – two simple measures outperform current standards. Podium session presented at: ISPOR 15th Annual International Meeting, Atlanta, GA, 15–19 May 2010
- Johnston SS, Sheehan J, Riehle E, et al. Development and validation of a U.S. administrative claims-based algorithm to classify patients with type 2 diabetes mellitus into renal impairment stages. Poster session presented at: ISPOR 20th Annual International Meeting, Philadelphia, PA, 16–20 May 2015
- Johnston SS, Sheehan J, Riehle E, et al. Estimated prevalence of renal impairment among patients with type 2 diabetes mellitus in the United States. Podium session presented at: 75th Scientific Sessions of the American Diabetes Association; Boston, MA, 5–9 June 2015
- Gibson TB, Song X, Alemayehu B, et al. Cost sharing, adherence, and health outcomes in patients with diabetes. Am J Manag Care 2010;16:589-600
- Farr AM, Sheehan JJ, Curkendall SM, et al. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus. Adv Ther 2014;31:1287-305
- Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26
- Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399-424
- Normand ST, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol 2001;54:387-98
- Rascati KL, Worley K, Meah Y, Everhart D. Adherence, persistence, and health care costs for patients receiving dipeptidyl peptidase-4 inhibitors. J Manag Care Spec Pharm 2017;23:299-306
- AstraZeneca. Onglyza prescribing information. February 2017. Available at: http://www.azpicentral.com/onglyza/pi_onglyza.pdf [Last accessed 25 May 2017]
- Boehringer Ingelheim. Tradjenta prescribing information. March 2017. Available at: http://docs.boehringer-ingelheim.com/Pres-cribing%20Information/PIs/Tradjenta/Tradjenta.pdf?DMW_FORMAT=pdf [Last accessed 25 May 2017]
- Farr AM, Sheehan JJ, Davis BM, Smith DM. Comparison of adherence and persistence among adults with type 2 diabetes mellitus initiating saxagliptin or linagliptin. Patient Prefer Adherence 2016;10:1471-9